| Schedule of Segment Information |
The following represents
selected financial information for our segments for the three and nine months ended July 31, 2020 and 2019 and as of July 31, 2020
and October 31, 2019:
| |
|
For the Three Months Ended
July 31, |
|
|
For the Nine Months Ended
July 31, |
|
| |
|
2020 |
|
|
2019 |
|
|
2020 |
|
|
2019 |
|
| Net Loss: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
(402,223 |
) |
|
$ |
(723,128 |
) |
|
$ |
(1,527,586 |
) |
|
$ |
(4,240,347 |
) |
| Cancer Vaccines |
|
|
(172,881 |
) |
|
|
(573,005 |
) |
|
|
(538,748 |
) |
|
|
(573,005 |
) |
| Anti-Viral Therapeutics |
|
|
(268,704 |
) |
|
|
- |
|
|
|
(578,208 |
) |
|
|
- |
|
| Cancer Diagnostics |
|
|
(1,727,256 |
) |
|
|
(876,667 |
) |
|
|
(5,196,929 |
) |
|
|
(3,929,021 |
) |
| Patent Licensing |
|
|
(5,723 |
) |
|
|
6,752 |
|
|
|
(9,881 |
) |
|
|
(965,218 |
) |
| Total |
|
$ |
(2,576,787 |
) |
|
$ |
(2,166,048 |
) |
|
$ |
(7,851,352 |
) |
|
$ |
(9,707,591 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total operating costs and expenses |
|
$ |
2,584,053 |
|
|
$ |
2,184,412 |
|
|
$ |
7,884,059 |
|
|
$ |
10,011,374 |
|
| Less non-cash share-based compensation |
|
|
(1,041,799 |
) |
|
|
(830,898 |
) |
|
|
(3,173,219 |
) |
|
|
(4,902,512 |
) |
| Operating costs and expenses excluding non-cash share-based compensation |
|
$ |
1,542,254 |
|
|
$ |
1,353,514 |
|
|
$ |
4,710,840 |
|
|
$ |
5,108,862 |
|
| Operating costs and expenses excluding non-cash share based compensation: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
182,007 |
|
|
$ |
442,621 |
|
|
$ |
752,170 |
|
|
$ |
1,688,301 |
|
| Cancer Vaccines |
|
|
70,061 |
|
|
|
407,010 |
|
|
|
235,391 |
|
|
|
407,010 |
|
| Anti-Viral Therapeutics |
|
|
149,075 |
|
|
|
- |
|
|
|
370,093 |
|
|
|
- |
|
| Cancer Diagnostics |
|
|
1,136,629 |
|
|
|
487,169 |
|
|
|
3,345,441 |
|
|
|
1,905,137 |
|
| Patent Licensing |
|
|
4,482 |
|
|
|
16,714 |
|
|
|
7,745 |
|
|
|
1,108,414 |
|
| Total |
|
$ |
1,542,254 |
|
|
$ |
1,353,514 |
|
|
|
4,710,840 |
|
|
$ |
5,108,862 |
|
| |
|
July 31,
2020 |
|
|
October 31,
2019 |
|
| Total assets: |
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
4,110,341 |
|
|
$ |
2,382,460 |
|
| Cancer Vaccines |
|
|
1,575,525 |
|
|
|
489,881 |
|
| Anti-Viral Therapeutics |
|
|
3,349,814 |
|
|
|
- |
|
| Cancer Diagnostics |
|
|
78,723 |
|
|
|
3,119,246 |
|
| Patent Licensing |
|
|
247,378 |
|
|
|
302,106 |
|
| Total |
|
$ |
9,361,781 |
|
|
$ |
6,293,693 |
|
|